newsfilter
← Latest News
GlobeNewswire·

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on